MDCG gui­dance on the tran­si­tio­nal pro­vi­si­ons in Artic­le 120 MDR

Tran­si­tio­nal rules of Artic­le 120 MDR

Artic­le 120, Para­graphs (2) and (3) of the Medi­cal Devices Regu­la­ti­on (EU) 2017/745 (MDR) (PDF) sta­te that devices for which valid cer­ti­fi­ca­tes are available that were still issued by a Noti­fied Body under the Acti­ve Implan­ta­ble Medi­cal Devices Direc­ti­ve 90/385/EEC (AIMDD) or the Medi­cal Devices Direc­ti­ve 93/42/EEC (MDD) can still be pla­ced on the mar­ket or put into ser­vice after the MDR beco­mes appli­ca­ble. Pre­re­qui­si­te for this is that the Noti­fied Body that issued the rele­vant cer­ti­fi­ca­te in accordance with the MDD or the AIMDD con­ti­nues to car­ry out, or is able to car­ry out, appro­pria­te sur­veil­lan­ce of all requi­re­ments for the devices it has cer­ti­fied. Gui­dance Docu­ment 2022–4 (PDF) sum­ma­ri­ses what is expec­ted of both manu­fac­tu­r­ers and Noti­fied Bodies with respect to “appro­pria­te sur­veil­lan­ce” under Artic­le 120 MDR.

QMS requi­re­ments: MDD vs. MDR

In par­ti­cu­lar, to cla­ri­fy the ele­ments to be review­ed by Noti­fied Bodies, the gui­dance docu­ment explains cer­tain obli­ga­ti­ons of manu­fac­tu­r­ers with respect to their qua­li­ty manage­ment systems.

Artic­le 120(3) MDR requi­res that devices still pla­ced on the mar­ket or put into ser­vice under MDD/AIMDD cer­ti­fi­ca­ti­on con­ti­nue to com­ply with eit­her of the­se Direc­ti­ves and do not under­go signi­fi­cant chan­ges in design or inten­ded use. The­r­e­fo­re, in prin­ci­ple, the qua­li­ty manage­ment sys­tem appro­ved in accordance with the gui­de­lines must be main­tai­ned. Howe­ver, accor­ding to the first sub­pa­ra­graph of Artic­le 120(3) MDR, all appli­ca­ble requi­re­ments of Chap­ter VII of the MDR on post-market sur­veil­lan­ce, mar­ket sur­veil­lan­ce, vigi­lan­ce and regis­tra­ti­on of eco­no­mic ope­ra­tors for exis­ting pro­ducts must be obser­ved ins­tead of the cor­re­spon­ding requi­re­ments in the Directives.

MDR requi­re­ments other than post-market sur­veil­lan­ce, mar­ket sur­veil­lan­ce, vigi­lan­ce, regis­tra­ti­on of eco­no­mic ope­ra­tors and pro­ducts should in prin­ci­ple not app­ly to eco­no­mic ope­ra­tors in rela­ti­on to exis­ting products. 

This is whe­re the gui­dance docu­ment pro­ves par­ti­cu­lar­ly hel­pful to manu­fac­tu­r­ers by pro­vi­ding a com­pa­ra­ti­ve table of the qua­li­ty manage­ment sys­tem requi­re­ments in the MDD and MDR, which manu­fac­tu­r­ers can use to cla­ri­fy which MDD or AIMDD requi­re­ments are cover­ed by the MDR and which are not.

Gui­dance for Noti­fied Bodies and super­vi­so­ry authorities

Fur­ther­mo­re, the docu­ment pro­vi­des infor­ma­ti­on on the scope of duties of Noti­fied Bodies and super­vi­so­ry aut­ho­ri­ties with regard to pro­duct sur­veil­lan­ce of exis­ting pro­ducts during the tran­si­tio­nal pro­vi­si­ons, which can also be used by manu­fac­tu­r­ers to see what expec­ta­ti­ons they must reck­on with regar­ding their exis­ting pro­ducts in the con­text of audits and inspections.

Recom­men­da­ti­on for action

The Coor­di­na­ti­on Group’s gui­dance docu­ments do not reflect the offi­ci­al posi­ti­on of the Euro­pean Com­mis­si­on. Hence, the recom­men­da­ti­ons are not legal­ly bin­ding. Nevert­hel­ess, they are to be unders­tood as a valuable inter­pre­ta­ti­on aid for eco­no­mic ope­ra­tors to com­pre­hend the still new MDR and IVDR. Manu­fac­tu­r­ers should keep an eye on MDCG publi­ca­ti­ons and check them in terms of rele­van­ce to their own pro­ducts. Fol­lo­wing the gui­dance docu­ments and set­ting up pro­ducts in accordance with them can signi­fi­cant­ly help to avo­id “trou­ble” with Noti­fied Bodies and regu­la­to­ry aut­ho­ri­ties when com­pli­ance with the appli­ca­ble regu­la­ti­ons is questioned.


Stay up-to-date

We use your email address exclusively for sending our newsletter. You have the right to revoke your consent at any time with effect for the future. For further information, please refer to our privacy policy.